In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner

Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.